Results 221 to 230 of about 133,537 (299)

Safety and Efficacy of Concomitant Administration of Nanoliposomal Irinotecan + 5‐Fluorouracil/Levo‐Leucovorin for Pancreatic Cancer

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background Nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil (5‐FU)/levo‐leucovorin (Levo‐LV) therapy is recommended as the standard of care for unresectable locally advanced (UR‐LA) and metastatic pancreatic cancer after failure of gemcitabine‐containing regimens.
Akane Wakabayashi, Rei Tanaka, Yurie Fukumuro, Keita Mori, Junya Sato, Hiroshi Ishikawa, Michihiro Shino, Takeshi Kawakami   +7 more
wiley   +1 more source

Exportin 1 inhibitor KPT‑330 reverses oxaliplatin resistance via p53 nuclear retention in colorectal cancer. [PDF]

Int J Mol Med
Lai C, Jia X, Chen Y, Chen K, Wang F, Zhang Q, Xiang X, Chen ZS, Xu L, Dai S.   +9 more
europepmc   +1 more source

Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 403-413, February 2026.
Circulating tumor cells (CTCs) and tumor‐derived extracellular vesicles (tdEVs) are promising biomarkers for predicting survival and informing treatment decisions in metastatic colorectal cancer (mCRC); yet their clinical application remains limited. In this study, we analyzed CellSearch image archives from 446 patients with mCRC treated in the CAIRO2 ...
Maddalena Centanni, Afroditi Nanou, Leon W. M. M. Terstappen, Kees J. A. Punt, Frank A.W. Coumans, Mats O. Karlsson, Lena E. Friberg   +6 more
wiley   +1 more source

Comparative Binding Affinities of Platinum-Based Drugs toward Purine Alkaloids and Nucleobases. [PDF]

ACS Omega
Szefler B, Szupryczyński K.
europepmc   +1 more source

Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Abstract Objective To explore the efficacy and safety of surufatinib in combination with anti‐PD‐1/PD‐L1 antibodies (with or without chemotherapy) in patients with advanced BTC after failure of first‐line treatment. Methods 24 patients with advanced BTC who failed first‐line treatment were admitted to our centre from March 2023 to August 2024 and ...
Xinni Chen, Feng Wang, Yuan Cheng, Mengran Cao, Kuimin Mei, Xiaoyuan Chu, Fang Dai, Xinlei Gong   +7 more
wiley   +1 more source

Peroneal Nerve Palsy With Foot Drop: A Rare Manifestation of Oxaliplatin Toxicity. [PDF]

Cureus
Couto MC, Ribeiro MJ, Barbosa M, Tavares NT.   +3 more
europepmc   +1 more source

Total neoadjuvant therapy in rectal cancer: The FOREST protocol, a patient‐centered approach that clusters two cohorts with different outcomes

International Journal of Cancer, Volume 158, Issue 3, Page 697-706, 1 February 2026.
What's new? Treatment strategies for rectal cancer are increasingly focused on organ preservation and tailored therapy. Total neoadjuvant therapy (TNT), which integrates radiotherapy and systemic chemotherapy prior to surgery, is especially promising in this regard.
Hector Guadalajara, Jose Luis Domínguez‐Tristancho, Raquel Fuentes Mateo, Miguel Leon‐Arellano, Raquel Sanz‐Baro, Eleonora Geraldi, Ana Isabel Hormigo‐Sanchez, Víctor Manuel Castellano Megías, Marta Pérez Cobos, Patricia Mellado Miras, Begoña Lopez‐Botet Zulueta, Mariano Garcia‐Arranz, Jesus García Foncillas, Cristina Caramés, Damián García‐Olmo   +14 more
wiley   +1 more source

Patient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer. [PDF]

Clin Cancer Res
Smabers LP, Wensink GE, Verissimo CS, Doorn M, Yang T, Voskuilen T, Huismans MA, Valkenburg-van Iersel LBJ, Cirkel GA, Gootjes EC, Verheul HMW, Jeurissen FJ, Bol GM, Nienhuis HH, Braat MNGJA, Cuppen E, Vries RGJ, van der Baan FH, Elias SG, Kranenburg O, Koopman M, Boj SF, Roodhart JML.   +22 more
europepmc   +1 more source

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS‐wild‐type metastatic colorectal cancer treated with first‐line panitumumab plus FOLFIRI/FOLFOX: Final results of the non‐interventional study VALIDATE

International Journal of Cancer, Volume 158, Issue 3, Page 716-727, 1 February 2026.
What's new? Prognostic assessment in metastatic colorectal cancer (mCRC), which is currently based on scores derived from clinical trials, requires refinement to enhance treatment outcomes and quality of care. In this study, the authors evaluated real‐world data from the German tumor registry to prospectively validate a modified mCRC prognostic score ...
Karin Potthoff, Jens Uhlig, Lutz Jacobasch, Lothar Müller, Marcel Reiser, Rebecca de Buhr, Silke Polata, Armin Gerger, Viktor Zehrer, Arno Amann, Thomas Göhler, Laura Serrer, Jan Schröder, Dieter Semsek, Andreas Köhler, Patrick Stübs, Gerald Prager, Hans Ulrich Siebenbach, Anita Schuch, Norbert Marschner   +19 more
wiley   +1 more source